Evidence map›Paper›PMID 34781266›Full record

ReviewJournal of the National Comprehensive Cancer Network : JNCCN2021

Survivorship Issues in Adult Patients With Histiocytic Neoplasms.

Kevin O'Brien, Rahul Dave, Skand Shekhar, Fady Hannah-Shmouni, Leora E Comis, Beth I Solomon, Marcus Chen, William A Gahl, Edmond FitzGibbon, Bernadette R Gochuico and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the National Comprehensive Cancer Network : JNCCN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kevin O'BrienOffice of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, Maryland.
Rahul DaveInova Fairfax-Virginia Commonwealth University College of Medicine, Falls Church, Virginia.
Skand ShekharClinical Research Branch, National Institute of Environmental Health Sciences, NIH, Bethesda, Maryland.
Fady Hannah-ShmouniEunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland.
Leora E ComisRehabilitation Medicine Department, Clinical Center, NIH, Bethesda, Maryland.
Beth I SolomonSpeech Language Pathology Section, Rehabilitation Medicine Department, Mark O. Hatfield Clinical Research Center, NIH, Bethesda, Maryland.
Marcus ChenNational Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; and.
William A GahlOffice of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, Maryland.
Edmond FitzGibbonNational Eye Institute, NIH, Bethesda, Maryland.
Bernadette R GochuicoOffice of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, Maryland.
Juvianee I Estrada-VerasOffice of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, Maryland.

Funding

Intramural NIH HHS Z99 HG999999
6 · The paper itself

Abstract

Adult-onset histiocytoses (AOH), primarily Rosai-Dorfman disease (RDD), Erdheim-Chester Disease (ECD), and adult Langerhans cell histiocytosis (ALCH), are a group of related histiocytic neoplastic disorders featuring multisystemic manifestations. The disorders are largely incurable, and are essentially chronic neoplastic diseases with a variable prognosis. Prompt diagnosis and treatment is important to prevent debilitating and even life-threatening complications. Survivorship issues abound in AOH, due to their multisystemic manifestations and the sometimes recalcitrant chronic inflammation, which can lead to other debilitating complications such as fatigue, weakness, and pain. Because these disorders are rare, few healthcare professionals are proficient in their management; therefore the aim of these guidelines is to offer guidance on how to manage patients, and how to create survivorship care plans through the efforts of an interdisciplinary team.

Indexed as

Erdheim-Chester DiseaseHistiocytosis, Langerhans-CellHistiocytosis, SinusNeoplasmsAdultHumansPrognosisSurvivorship

Identifiers

PMID34781266
PMCPMC10481619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.